<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03463512</url>
  </required_header>
  <id_info>
    <org_study_id>RACE3003</org_study_id>
    <nct_id>NCT03463512</nct_id>
  </id_info>
  <brief_title>Controlled Study to Evaluate the Efficacy and Safety of Racecadotril in Infants, Children and Adolescents With Acute Diarrhea</brief_title>
  <official_title>Multicenter, Open-label, Controlled, Randomized Clinical Study to Evaluate the Efficacy and Safety of Racecadotril in Infants, Children and Adolescents With Acute Diarrhea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicenter, open-label, controlled, randomized clinical study to evaluate the efficacy and
      safety of Racecadotril in infants, children and adolescents with acute diarrhea
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 13, 2018</start_date>
  <completion_date type="Anticipated">March 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 15, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of diarrhea (hours) between the start of treatment until last diarrheal/watery stool before recovery or end of study treatment (treatment duration maximal 5 days)</measure>
    <time_frame>5 days</time_frame>
    <description>Duration of diarrhea is defined by date and time of the evacuation of the final diarrheal stool derived from the daily diary</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of recovered subjects per treatment group</measure>
    <time_frame>5 days</time_frame>
    <description>Number of recovered subjects per treatment group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Physician Assessment at the end of treatment</measure>
    <time_frame>5 days</time_frame>
    <description>scores 1-6</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Diarrhea</condition>
  <arm_group>
    <arm_group_label>Racecadotril plus standard treatment oral rehydration solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ORS (standard treatment)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Racecadotril plus ORS</intervention_name>
    <description>Racecadotril plus ORS</description>
    <arm_group_label>Racecadotril plus standard treatment oral rehydration solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ORS</intervention_name>
    <description>ORS</description>
    <arm_group_label>ORS (standard treatment)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent from one of the parent(s)/caregiver(s) or subject informed
             assent

          -  Children and adolescents, both genders, age from 3 months to &lt; 18 years of age

          -  Confirmed diagnosis of acute diarrhea (defined as the passage of three or more
             unformed or liquid stools within the last 24 hours and lasting for less than three
             days)

          -  Females of child-bearing potential should agree to continue using a medically
             acceptable method of birth control throughout the study and for 30 days immediately
             after the last dose of study drug. Medically acceptable methods of birth control
             include bilateral tubal ligation or the use of either a contraceptive implant, a
             contraceptive injection, an intrauterine device, or an oral contraceptive taken within
             the past three months where the subject agrees to continue using during the study or
             to adopt another birth control method, or a double-barrier method which consists of a
             combination of any two of the following: diaphragm, cervical cap, condom, or
             spermicide

        Exclusion Criteria:

          -  Known allergy to Racecadotril or any of its ingredients

          -  Subjects suffering from renal or hepatic impairment

          -  Subjects who need treatment for diarrhea other than ORS alone

          -  Subjects with fever &gt; 39 degrees Celsius

          -  Subjects with bloody and/or purulent stools

          -  Subjects suffering from antibiotic-associated diarrhea, chronic diarrhea or iatrogenic
             diarrhea

          -  Subjects with alternating bouts of diarrhea and constipation

          -  Diarrhea due to exacerbation of chronic gastrointestinal diseases such as irritable
             bowel syndrome, inflammatory bowel disease or pancreatic exocrine insufficiency

          -  Cystic fibrosis or coeliac disease

          -  Subjects suffering from prolonged or uncontrolled vomiting

          -  Subjects with rare hereditary problems of fructose or galactose intolerance, Lapp
             lactase deficiency, glucose-galactose malabsorption syndrome or sucrase isomaltase
             insufficiency or primary or secondary lactase insufficiency

          -  Subjects having received antibiotic treatment at any time within 30 days prior to
             inclusion into the study

          -  Subjects having received antidiarrheal drugs 48 hours prior to inclusion into the
             study

          -  Subjects with severe dehydration required for intravenous/parenteral rehydration

          -  Subjects who have reported angioedema with angiotensin converting enzyme inhibitors
             (such as captopril, enalapril, lisinopril, perindopril, ramipril)

          -  Subjects with combined diseases or medical situations that would prevent to be
             enrolled depending in the judgment of the investigator

          -  Intake of experimental drug within 30 days prior to study start

          -  Subjects with contraindications to ORS or for whom warnings/precautions of ORS apply

          -  Adolescents (â‰¥ 60 kg) not able to swallow capsules

          -  Pregnancy and lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Suntje Sander</last_name>
    <phone>+49 511 6750</phone>
    <phone_ext>3254</phone_ext>
    <email>suntje.sander@abbott.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Saint Petersburg State Budgetary Healthcare Institution &quot;Municipal Outpatient Children Unit #45&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 5, 2018</study_first_submitted>
  <study_first_submitted_qc>March 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2018</study_first_posted>
  <last_update_submitted>March 21, 2018</last_update_submitted>
  <last_update_submitted_qc>March 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Racecadotril</mesh_term>
    <mesh_term>Thiorphan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

